Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany?

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 2045-2051

  Terschuren C ^a   Gierer, S ^a   Brillant, C ^b   Paulus, U ^b   Loffler M ^c   Hoffmann, W ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Generalizability; High grade non Hodgkin lymphoma; Hodgkin lymphoma; Inclusion criteria; Population based analysis; Therapy optimization protocol

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GERMANY; HEALTH SURVEY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; THERAPY OPTIMIZATION PROTOCOL;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; GERMANY; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77957137408     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq214     Document Type: Article

References (37)

1. Rusthoven JJ. Current approaches to the treatment of advanced-stage Hodgkin's disease. CMAJ 1986; 135: 465-473.
2. Foltz LM, Song KW, Connors JM. Hodgkin's lymphoma in adolescents. J Clin Oncol 2006; 24(16): 2520-2526.
3. Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008; 111(6): 2977-2983.
4. Sweet DL, Kinzie J, Gaeke ME et al. Survival of patients with localized diffuse histiocytic lymphoma. Blood 1981; 58(6): 1218-1223.
5. Bernard M, Cartron G, Rachieru P et al. Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study. Haematologica 2005; 90(6): 802-809.
6. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from 1990s to the early 21st century. Arch Intern Med 2008; 168(5): 469-476.
7. Hoffmann W, Terschüren C, Heimpel H et al. Population-based research on occupational and environmental factors for leukemia and non-Hodgkin's lymphoma: the Northern Germany Leukemia and Lymphoma Study (NLL). Am J Ind Med 2008; 51: 246-257.
8. Dühmke E, Franklin J, Pfreundschuh M et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001; 19(11): 2905-2914.
9. Sieber M, Tesch H, Pfistner B et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 2002; 20(2): 476-484.
10. Sieber M, Tesch H, Pfistner B et al. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol 2004; 15(2): 276-282.
11. Engert A, Schiller P, Josting A et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21(19): 3601-3608.
12. Ballova V, Ruffer JU, Haverkamp H et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005; 16(1): 124-131.
13. Engert A, Franklin J, Eich HT et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25(23): 3495-3502.
14. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348(24): 2386-2395.
15. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104(3): 626-633.
16. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104(3): 634-641.
17. Schmits R, Glass B, Trumper L et al. Therapeutic strategies for aggressive lymphomas: the trials of the GSHNHL. Ann Hematol 2001; 80 (Suppl 3): B77-B83.
18. Richardson DB, Terschüren C, Hoffmann W. Occupational risk factors for non-Hodgkin's lymphoma: a population-based case-control study in Northern Germany. Am J Ind Med 2008; 51: 258-268.
19. Corrie P, Shaw J, Harris R. Rate limiting factors in recruitment of patients to clinical trials in cancer research: descriptive study. Br Med J 2003; 327: 320-321.
20. Stone JM, Page FJ, Laidlaw CR et al. Selection of patients for randomised trials: a study based on the MACOP-B vs CHOP in NHL study. Aust N Z J Med 1994; 24(5): 536-540.
21. Van Spall HGC, Toren A, Kiss A et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007; 297(11): 1233-1240.
22. Hartge P, Devesa SS, Fraumeni JF. Hodgkin's and non-Hodgkin's lymphomas. Cancer Surv 1994; 19-20: 423-453.
23. Medeiros LJ, Greiner TC. Hodgkin's disease. Cancer 1995; 75 (Suppl 1): 357-369.
24. Mueller N. Hodgkin's disease. In Schottenfeld D, Fraumeni JFJ (eds): Cancer Epidemiology and Prevention. New York: Oxford University Press 1996; 893-919.
25. Scherr PA, Mueller NE. Non-Hodgkin's lymphomas. In Schottenfeld D, Fraumeni JFJ (eds): Cancer Epidemiology and Prevention. New York: Oxford University Press 1996; 920-945.
26. Groves FD, Linet MS, Travis LB et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92(15): 1240-1251.
27. EUROSTAT. Bevölkerung und soziale Bedingungen: Bevölkerungsvorausschätzungen. [Population and Social Determinants: Population Forecasting]. http://epp.eurostat.ec.europa.eu/portal/page?_pageid=0,1136184,0_45572595&_dad=portal&_schema=PORTAL (15 May 2006, date last accessed).
28. Levis A, Anselmo AP, Ambrosetti A et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 2004; 15: 123-128.
29. Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park) 2008; 22(12): 1369-1379.
30. Klimm B, Eich HT, Haverkamp H et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 2007; 18(2): 357-363.
31. Michallet AS, Coiffier B. Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 2009; 23(1): 11-23.
32. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE et al. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 2005; 41(7): 1051-1057.
33. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36(4): 453-471.
34. Meropol NJ, Buzgalo JS, Milard J et al. Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw 2007; 5(8): 655-664.
35. Peters FP, Fickers MM, Erdkamp FL et al. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. Ann Hematol 2006; 80(7): 406-410.
36. van Agthoven M, Sonneveld P, Hagenbeek A et al. A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma. Hematol J 2003; 4: 399-409.
37. Peppercorn JM, Weeks JC, Cook EF et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004; 363(9405): 263-270.